NCT06296875 The Krill Ageing Muscle Mechanisms (KAMM) Study
| NCT ID | NCT06296875 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Glasgow |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-09-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length). Objective 2) Neuromuscular control and central nervous system (CNS) function Hypothesis: Krill oil supplementation will improve Neuromuscular Junction (NMJ) transmission stability and increase central drive and intramuscular coherence, as a measure of muscle synergy. Objective 3) Gait and functional characteristics Hypothesis: Krill oil supplementation will improve gait and functional characteristics.
Eligibility Criteria
Inclusion Criteria: * body mass index (BMI) \</= 30 kg/m2 * Age \>/= 65 years * Capacity to consent * Living within the Glasgow area Exclusion Criteria: * Diabetes mellitus * Severe cardiovascular disease * Seizure disorders * Uncontrolled hypertension (\>150/90mmHg) * Active cancer or cancer that has been in remission \<5 years * Participation in any resistance exercise training within the last 6 months * Impairments which may limit ability to perform assessments of muscle function * Dementia * Fish/shellfish allergy * Taking medication known to affect muscle (e.g. steroids, Selective serotonin reuptake inhibitors) or anticoagulants (e.g. warfarin) * Taking omega-3 supplements in the last 3 months * Regularly consuming 1 or more portions of oily fish per week * Not able to understand English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06296875 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 90 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06296875 currently recruiting?
Yes, NCT06296875 is actively recruiting participants. Contact the research team at stuart.gray@glasgow.ac.uk for enrollment information.
Where is the NCT06296875 trial being conducted?
This trial is being conducted at Glasgow, United Kingdom.
Who is sponsoring the NCT06296875 clinical trial?
NCT06296875 is sponsored by University of Glasgow. The trial plans to enroll 80 participants.